Search results
Showing 751 to 800 of 1835 results for carers
In development Reference number: GID-TA11766 Expected publication date: TBC
Awaiting development Reference number: GID-TA11724 Expected publication date: TBC
In development Reference number: GID-TA11644 Expected publication date: 22 October 2026
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]
Awaiting development Reference number: GID-TA11606 Expected publication date: TBC
In development Reference number: GID-TA11592 Expected publication date: TBC
In development Reference number: GID-TA11625 Expected publication date: TBC
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
In development Reference number: GID-TA11687 Expected publication date: TBC
In development Reference number: GID-TA11804 Expected publication date: 08 October 2026
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]
In development Reference number: GID-TA11780 Expected publication date: TBC
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
Awaiting development Reference number: GID-TA11281 Expected publication date: TBC
In development Reference number: GID-TA11342 Expected publication date: TBC
Interim methods guide for developing good practice guidance (PMG15)
This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance
In development Reference number: GID-TA11650 Expected publication date: TBC
Awaiting development Reference number: GID-TA11747 Expected publication date: 14 April 2027
This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
Awaiting development Reference number: GID-TA11216 Expected publication date: TBC
In development Reference number: GID-TA11199 Expected publication date: TBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]
Awaiting development Reference number: GID-TA11303 Expected publication date: TBC
Awaiting development Reference number: GID-TA11219 Expected publication date: TBC
In development Reference number: GID-IPG10392 Expected publication date: TBC
In development Reference number: GID-TA11749 Expected publication date: 10 June 2027
In development Reference number: GID-TA11693 Expected publication date: TBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]
In development Reference number: GID-TA11688 Expected publication date: TBC
In development Reference number: GID-TA11660 Expected publication date: TBC
In development Reference number: GID-TA11842 Expected publication date: TBC
In development Reference number: GID-TA11773 Expected publication date: TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
In development Reference number: GID-TA11116 Expected publication date: 29 July 2026
Awaiting development Reference number: GID-TA10972 Expected publication date: TBC
Artificial intelligence technologies for mammography: early value assessment
Awaiting development Reference number: GID-HTE10062 Expected publication date: TBC
Awaiting development Reference number: GID-TA11670 Expected publication date: TBC
In development Reference number: GID-TA11308 Expected publication date: TBC
In development Reference number: GID-TA11094 Expected publication date: TBC
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]
Awaiting development Reference number: GID-TA10971 Expected publication date: TBC
The guidance development timeline
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.
In development Reference number: GID-TA11760 Expected publication date: TBC
In development Reference number: GID-TA11823 Expected publication date: TBC
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Awaiting development Reference number: GID-TA11087 Expected publication date: TBC
Awaiting development Reference number: GID-TA11639 Expected publication date: TBC
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]
Awaiting development Reference number: GID-TA11855 Expected publication date: TBC
Awaiting development Reference number: GID-TA11624 Expected publication date: TBC
for people growing older with learning disabilities, and their family members and carers?What processes are in place to document and...
This quality standard covers the effective use of antimicrobial medicines (including antibiotics) to reduce the risk of antimicrobial resistance, which is when antimicrobial medicines lose their effectiveness. It covers all settings and all types of antimicrobials for treating bacterial, fungal, viral and parasitic infections. It describes high-quality care in priority areas for improvement.
View quality statements for QS121Show all sections
Sections for QS121
- Quality statements
- Quality statement 1: Advice on self-limiting conditions
- Quality statement 2: Back-up (delayed) prescribing
- Quality statement 3: Recording information
- Quality statement 4: Microbiological samples
- Quality statement 5: Data collection and feedback
- Quality statement 6 (developmental statement): electronic prescribing systems
- Update information
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]
Awaiting development Reference number: GID-TA11218 Expected publication date: TBC
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]
Awaiting development Reference number: GID-TA11458 Expected publication date: TBC
Awaiting development Reference number: GID-TA11500 Expected publication date: TBC